Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOAR: Eltrombopag + Cyclosporine in Severe Aplastic Anemia
NCT02998645Phase 2Completed
- Sponsor
- Novartis
- Start
- May 2017
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, open-label, single-arm trial of eltrombopag in aplastic anemia, sponsored by Novartis. Primary endpoint: Overall Hematologic Response Rate at 6 months. Started May 2017; status: completed.
02
Drugs
eltrombopag
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on NCT02998645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02998645.